US 4626504A
· Puhler
· 1986
[cited by applicant]
US 5633154A
· Schaefer
· 1997
[cited by applicant]
US 8241498B2
· Summer
· 2012
[cited by applicant]
US 8252576B2
· Campbell
· 2012
[cited by applicant]
US 8906682B2
· June
· 2014
[cited by applicant]
US 8911993B2
· June
· 2014
[cited by applicant]
US 8916381B1
· June
· 2014
[cited by applicant]
US 8975071B1
· June
· 2015
[cited by applicant]
US 9101584B2
· June
· 2015
[cited by applicant]
US 9102760B2
· June
· 2015
[cited by applicant]
US 9102761B2
· June
· 2015
[cited by applicant]
US 9113616B2
· MacDonald et al.
· 2015
[cited by applicant]
US 9328156B2
· June
· 2016
[cited by applicant]
US 9464140B2
· June
· 2016
[cited by applicant]
US 9481728B2
· June
· 2016
[cited by applicant]
US 9499629B2
· June
· 2016
[cited by applicant]
US 9518123B2
· June
· 2016
[cited by applicant]
US 9540445B2
· June
· 2017
[cited by applicant]
US 9701964B2
· Clube
· 2017
[cited by applicant]
US 20040096974A1
· Herron
· 2004
[cited by applicant]
US 20050118719A1
· Schmidt
· 2005
[cited by applicant]
US 20140370017A1
· June
· 2014
[cited by applicant]
US 20150050699A1
· Siksnys
· 2015
[cited by applicant]
US 20150050729A1
· June
· 2015
[cited by applicant]
US 20150290244A1
· June
· 2015
[cited by applicant]
US 20160009805A1
· Kowanetz
· 2016
[cited by applicant]
US 20160081314A1
· Thurston
· 2016
[cited by applicant]
US 20160115489A1
· Zhang
· 2016
[cited by applicant]
US 20160168594A1
· Zhang
· 2016
[cited by examiner]
US 20160347836A1
· Grosso
· 2016
[cited by applicant]
US 20170022499A1
· Lu
· 2017
[cited by applicant]
US 20170173086A1
· Boyle et al.
· 2017
[cited by applicant]
US 20170175142A1
· Zhang
· 2017
[cited by applicant]
US 20170340733A1
· Cao
· 2017
[cited by applicant]
US 20180015131A1
· Gajewski
· 2018
[cited by applicant]
US 20180146681A1
· Clube
· 2018
[cited by applicant]
US 20180179547A1
· Zhang
· 2018
[cited by applicant]
US 20180200342A1
· Bikard
· 2018
[cited by applicant]
US 20190160120A1
· Haaber
· 2019
[cited by applicant]
US 20190230936A1
· Clube
· 2019
[cited by applicant]
US 20200068901A1
· Clube
· 2020
[cited by applicant]
US 20200077663A1
· Clube
· 2020
[cited by applicant]
US 20200085066A1
· Clube
· 2020
[cited by applicant]
US 20200128832A1
· Clube
· 2020
[cited by applicant]
US 20200164070A1
· Clube
· 2020
[cited by applicant]
US 20200205416A1
· Clube
· 2020
[cited by applicant]
US 20200254035A1
· Haaber
· 2020
[cited by applicant]
US 20210147827A1
· Clube
· 2021
[cited by applicant]
US 20210147857A1
· Clube
· 2021
[cited by applicant]
US 20210283167A1
· Clube
· 2021
[cited by applicant]
US 20210290654A1
· Clube
· 2021
[cited by applicant]
US 20210386773A1
· Clube
· 2021
[cited by applicant]
US 20220275380A1
· Porse
· 2022
[cited by applicant]
US 20220362280A1
· Clube
· 2022
[cited by applicant]
US 20230193241A1
· Clube et al.
· 2023
[cited by applicant]
US 20230330167A1
· Haaber
· 2023
[cited by applicant]
US 20240384279A1
· Munck et al.
· 2024
[cited by applicant]
US 20250002942A1
· Semsey et al.
· 2025
[cited by applicant]
US 20250043291A1
· Le Miere et al.
· 2025
[cited by applicant]
CN 105555948A
· 2016
[cited by applicant]
CN 107557378A
· 2018
[cited by applicant]
EP 2840140A1
· 2015
[cited by applicant]
EP 3132035B8
· 2020
[cited by applicant]
EP 3132036B8
· 2020
[cited by applicant]
EP 3630975A1
· 2020
[cited by applicant]
EP 3633032A2
· 2020
[cited by applicant]
EP 3634442A1
· 2020
[cited by applicant]
EP 3634473A1
· 2020
[cited by applicant]
RU 2531343C2
· 2014
[cited by applicant]
WO 2005046579A2
· 2005
[cited by applicant]
WO 2005046579A3
· 2005
[cited by applicant]
WO 2007025097A2
· 2007
[cited by applicant]
WO 2008108989A2
· 2008
[cited by applicant]
WO 2010011961A2
· 2010
[cited by applicant]
WO 2010075424A2
· 2010
[cited by applicant]
WO 2012079000A1
· 2012
[cited by applicant]
WO 2012079000A4
· 2012
[cited by applicant]
WO 2012164565A1
· 2012
[cited by applicant]
WO 2013063361A1
· 2013
[cited by applicant]
WO 2013176772A1
· 2013
[cited by applicant]
WO 2014012001A2
· 2014
[cited by applicant]
WO 2014018423A2
· 2014
[cited by applicant]
WO 2014124226A1
· 2014
[cited by applicant]
WO 2015034872A2
· 2015
[cited by applicant]
WO 2014012001A3
· 2015
[cited by applicant]
WO 2015058018A1
· 2015
[cited by applicant]
WO 2015069682A2
· 2015
[cited by applicant]
WO 2015071474A2
· 2015
[cited by applicant]
WO 2015088643A1
· 2015
[cited by applicant]
WO 2015089419A2
· 2015
[cited by applicant]
WO 2015089419A3
· 2015
[cited by applicant]
WO 2015136541A2
· 2015
[cited by applicant]
WO 2015148680A1
· 2015
[cited by applicant]
WO 2015155686A2
· 2015
[cited by applicant]
WO 2015159068A1
· 2015
[cited by applicant]
WO 2015159086A1
· 2015
[cited by applicant]
WO 2015159087A1
· 2015
[cited by applicant]
WO 2015136541A3
· 2015
[cited by applicant]
WO 2016033088A1
· 2016
[cited by applicant]
WO 2016044745A1
· 2016
[cited by applicant]
WO 2016063263A2
· 2016
[cited by applicant]
WO 2016177682A1
· 2016
[cited by applicant]
WO 2016196361A1
· 2016
[cited by applicant]
WO 2016196605A1
· 2016
[cited by applicant]
WO 2016205276A1
· 2016
[cited by applicant]
WO 2017029485A1
· 2017
[cited by applicant]
WO 2017042347A1
· 2017
[cited by applicant]
WO 2017058751A1
· 2017
[cited by applicant]
WO 2017112620A1
· 2017
[cited by applicant]
WO 2017118598A1
· 2017
[cited by applicant]
WO 2018064165A2
· 2018
[cited by applicant]
WO 2018069474A1
· 2018
[cited by applicant]
WO 2018081502A1
· 2018
[cited by applicant]
WO 2018141907A1
· 2018
[cited by applicant]
WO 2018217351A1
· 2018
[cited by applicant]
WO 2018217981A1
· 2018
[cited by applicant]
WO 2018222969A1
· 2018
[cited by applicant]
WO 2018226853A1
· 2018
[cited by applicant]
WO 2019002207A1
· 2019
[cited by applicant]
WO 2019002218A2
· 2019
[cited by applicant]
WO 2020072248A1
· 2020
[cited by applicant]
WO 2020072250A1
· 2020
[cited by applicant]
WO 2020072253A1
· 2020
[cited by applicant]
WO 2020072254A1
· 2020
[cited by applicant]
WO 2022063986A2
· 2022
[cited by applicant]
WO 2024184403A2
· 2024
[cited by applicant]
Leon (Leon et al. How bacteria control the CRISPR-Cas arsenal. Current Opinion in Microbiology 2018, 42:87-95) (Year: 2018).
[cited by examiner]
Vercoe (Vercoe et al. Cytotoxic Chromosomal Targeting by CRISPR/Cas Systems Can Reshape Bacterial Genomes and Expel or Remodel Pathogenicity Islands. 2013 PLOS Genetics; vol. 9 | Issue 4 | e1003454) (Year: 2013).
[cited by examiner]
Makarova et. al. An updated evolutionary classification of CRISPR-Cas systems. .2015 Nature Rev. Microbial., 13:722-736 (Year: 2015).
[cited by examiner]
Maikova et. al. New Insights Into Functions and Possible Applications of Clostridium difficile CRISPR-Cas System 2018 Frontiers In Microbiology, vol. 9, article 1740 (Year: 2018).
[cited by examiner]
Yao (Yao et al. CRISPR-Cas9/Cas12a biotechnology and application in bacteria. vol. 3, Issue 3, Sep. 2018, pp. 135-149) (Year: 2018).
[cited by examiner]
Anderson catalog (retrieved from <https://parts.igem.orc/Promoters/Catalog/Anderson>; 2014 from Wayback machine search (Year: 2014).
[cited by examiner]
Lim (Lim et al. Fundamental relationship between operon organization and gene expression. 2011. PNAS vol. 108, No. 26, 10626-10631) (Year: 2011).
[cited by examiner]
Aklujkar et al. (2010) “Interference With Histidyl-tRNA Synthetase By a CRISPR Spacer Sequence As a Factor In The Evolution Of Pelobacter Carbinolicus,” BMC Evolutionary Biology 10:203, 15 pages.
[cited by applicant]
American Lung Association (2019). “Preventing COPD,” retrieved from https://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/symptoms-causes-risk-factors/preventing-copd.html, last visited Aug. 5, 2019, 1 …
[cited by applicant]
Anderson Catalog, retrieved from https://parts.igem.org/Promoters/Catalog/Anderson lasted visited Nov. 29, 2018, 2 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23100, (Aug. 4, 2006), 3 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23101, (Aug. 4, 2006), 2 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23102, (Aug. 4, 2006), 1 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23103, (Aug. 4, 2006), 2 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23104, (Aug. 4, 2006), 2 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23105, (Aug. 14, 2006), 2 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23106, (Aug. 14, 2006), 5 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23107, (Aug. 17, 2006), 1 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23108, (Aug. 17, 2006), 3 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23109, (Aug. 17, 2006), 2 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23110, (Aug. 17, 2006), 2 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23111, (Aug. 17, 2006), 1 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23112, (Aug. 17, 2006), 1 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23113, (Aug. 17, 2006), 1 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23114, (Aug. 17, 2006), 2 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23115, (Aug. 17, 2006), 1 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23116, (Aug. 17, 2006), 1 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23117, (Aug. 17, 2006), 1 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23118, (Aug. 17, 2006), 1 pages.
[cited by applicant]
Anderson Promotor Collection, BBa_J23119, (Aug. 24, 2006), 3 pages.
[cited by applicant]
Ang, Y.L.E. et al. (2015). “Best Practice In The Treatment Of Advanced Squamous Cell Lung Cancer,” Ther. Adv. Respir. Dis. 9(5):224-235.
[cited by applicant]
Anonymous (Apr. 2016). “Checkpoint Inhibition: A Promising Immunotherapeutic Approach for Colorectal Cancer,” Oncology, 5(3):1-5, retrieved from http//www.personalizedmedonc.com/publications/prno/april-2016-vol-5-no-3/c…
[cited by applicant]
Arnold, I.C. et al. (Apr. 8, 2015, e-pub. Mar. 4, 2015). “Helicobacter Hepaticus Infection In BALB/c Mice Abolishes Subunit-Vaccine-Induced Protection Against M. Tuberculosis,” Vaccine 33(15):1808-1814.
[cited by applicant]
Arslan, Z. et al. (May 7, 2013). “RcsB-BglJ-Mediated Activation of Cascade Operon Does Not Induce The Maturation of CRISPR RNAs in
[cited by applicant]
Arumugam et al. (May 12, 2011). “Enterotypes of the human gut microbiome,” Nature 473(7346):174-180, 16 pages.
[cited by applicant]
Barrangou, R. et al. (Mar. 23, 2007). “CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes,” Science, 315:1709-1712.
[cited by applicant]
Barrett, K.J. et al. (1976). “Interactions Between A Satellite Bacteriophage and Its Helper,” J. Mol. Biol. 106:683-707.
[cited by applicant]
Beisel, C.L. et al. (2014). “A CRISPR Design For Next-Generation Antimicrobials,” Genome Biology 15:516, 4 pages.
[cited by applicant]
Belizario, J.E. et al. (Oct. 6, 2015). “Human Microbiomes and Their Roles In Dysbiosis, Common Diseases, and Novel Therapeutic Approaches,” Frontiers in Microbiology 6(1050):1-16.
[cited by applicant]
Bertram, R. et al. (2008). “The Application of Tet Repressor in Prokaryotic Gene Regulation and Expression,” Microbial Biotechnology 1(1):2-16.
[cited by applicant]
Bikard, D. et al. (2013, e-pub. Jun. 12, 2013). “Programmable Repression and Activation Of Bacterial Gene Expression Using an Engineered CRISPR-Cas System,” Nucleic Acids Research 41(15):7429-7437.
[cited by applicant]
Bikard, D. et al. (2017, e-pub. Sep. 6, 2017). “Using CRISPR-Cas Systems as Antimicrobials,” Current Opinion in Microbiology 37:155-160.
[cited by applicant]
Bikard, D. et al. (Aug. 16, 2012). “CRISPR Interference Can Prevent Natural Transformation and Virulence Acquisition during In Vivo Bacterial Infection,” Cell Host & Microbe 12(2):177-186.
[cited by applicant]
Bikard, D. et al. (Nov. 2014, e-pub. May 1, 2015). “Development of Sequence-Specific Antimicrobials Based On Programmable CRISPR-Cas Nucleases,” Nature Biotechnology 32(11):1146-1150, 16 pages.
[cited by applicant]
Broaders, E. et al. (Jul./Aug. 2013). “Mobile Genetic Elements Of The Human Gastrointestinal Tract,” Gut Microbes 4(4):271-280.
[cited by applicant]
Brouns, S.J.J. et al. (Aug. 15, 2008). Supplemental Material for “Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes,” Science 321:960-964.
[cited by applicant]
Brouns, S.J.J. et al. (Aug. 15, 2008).“Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes,” Science 321:960-964.
[cited by applicant]
Bryksin, A. V. et al. (Oct. 8, 2010). “Rational Design Of a Plasmid Origin That Replicates Efficiently In Both Gram-Positive and Gram-Negative Bacteria,” PloS One 5(10):e13244, 9 pages.
[cited by applicant]
Bugrysheva, J.V. et al. (Jul. 2011, E-Pub. Apr. 29, 2011). “The Histone-Like Protein Hip Is Essential For Growth Of
[cited by applicant]
Chan, B.K. et al. (2013). “Phage Cocktails and the Future of Phage Therapy,” Future Microbiol. 8(6):769-783.
[cited by applicant]
Chan, C.T.Y. et al. (Dec. 2015). “‘Deadman’ and ‘Passcode’ Microbial Kill Switches For Bacterial Containment,” Nat. Chem. Biol. 12(2):82-86.
[cited by applicant]
Chasteen, L. et al. (2006, e-pub. Nov. 6, 2006). “Eliminating Helper Phage From Phage Display,” Nucleic Acids Research 34(21):e145, 11 pages.
[cited by applicant]
Cheadle, E.J. et al. (2012). “Chimeric Antigen Receptors For T-Cell Based Therapy,” Methods Mol. Biol. 907:645-666, 36 pages.
[cited by applicant]
Chen, S. et al. (Feb. 2007, e-pub. Dec. 22, 2006). “Characterization of Strong Promoters From an Environmental Flavobacterium himernum Strain by Using a Green Fluorescent Protein-based Reporter System,” Applied and Envi…
[cited by applicant]
Christie, G.E. (1990). “Interactions Between Satellite Bacteriophage P4 and Its Helpers,” Annu. Rev. Genet. 24:465-490.
[cited by applicant]
Christie, G.E. (2012, e-pub. Nov. 3, 2012). “Pirates Of The Caudovirales,” Virology 434:210-221.
[cited by applicant]
Citorik, R.J. et al. (Nov. 2014, e-pub Sep. 21, 2014). “Sequence-Specific Antimicrobials Using Efficiently Delivered RNA-Guided Nucleases,” Nat. Biotechnol. 32(11):1141-1145, 18 pages.
[cited by applicant]
Cochrane, K. et al. (2016, e-pub. Nov. 3, 2015). “Complete Genome Sequences and Analysis Of The
[cited by applicant]
Coyne, M.J. et al. (2014). “Evidence of Extensive DNA Transfer between
[cited by applicant]
De Filippo, C. et al. (August 33 2010). “Impact Of Diet In Shaping Gut Microbiota Revealed By a Comparative Study In Children From Europe and Rural Africa,” Proc. Natl. Acad. Sci. USA 107(33):14691-14696, 6 pages.
[cited by applicant]
De Paepe, M. et al. (Mar. 28, 2014). “Bacteriophages: An Underestimated Role In Human and Animal Health?” Frontiers in Cellular and Infection Microbiology 4(39):1-11.
[cited by applicant]
Deeks, E.D. (2014, e-pub. Jul. 15, 2014). “Nivolumab: A Review Of Its Use In Patients With Malignant Melanoma,” Drugs 74:1233-1239.
[cited by applicant]
Deghorain, M. et al. (Nov. 23, 2012). “The Staphylococci Phages Family: An Overview,” Viruses 4:3316-3335.
[cited by applicant]
Dickson, R.P. et al. (Jan./Feb. 2017). “Bacterial Topography of the Healthy Human Lower Respiratory Tract,” American Society for Microbiology 8(1):e02287-6, 12 pages.
[cited by applicant]
Diez-Villasenor, C. et al. (May 2013). “CRISPR-Spacer Integration Reporter Plasmids Reveal Distinct Genuine Acquisition Specificities Among CROSPR-Cas 1-E Variants of
[cited by applicant]
Dutilh, B.E. et al. (Jul. 24, 2014). “A Highly Abundant Bacteriophage Discovered In The Unknown Sequences Of Human Faecal Metagenomes,” Nature Communications 5(4498):1-11.
[cited by applicant]
Edgar et al. (Dec. 2010). “The
[cited by applicant]
Ex Parte Re-Exam, mailed Dec. 10, 2018, for U.S. Appl. No. 90/014,184, filed Aug. 10, 2018, for Reexamination U.S. Pat. No. 9,701,964 102 pages.
[cited by applicant]
Extended European Search Report, dated Mar. 6, 2020, for European Patent Application No. 190202999.99, 10 pages.
[cited by applicant]
Extended European Search Report, dated May 10, 2021, for European Patent Application No. 20217137.7, 5 pages.
[cited by applicant]
Final Office Action, mailed Jul. 15, 2021, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 32 pages.
[cited by applicant]
Final Office Action, mailed Mar. 14, 2022, for U.S. Appl. No. 17/195,157, filed Mar. 8, 2021, 23 pages.
[cited by applicant]
Final Office Action, mailed May 29, 2020, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 10 pages.
[cited by applicant]
Final Office Action, mailed Nov. 14, 2022, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 88 pages.
[cited by applicant]
Final Office Action, mailed Sep. 28, 2021, for U.S. Appl. No. 17/166,941, filed Feb. 3, 2021, 22 pages.
[cited by applicant]
Foca, A. et al. (2015, e-pub. Apr. 7, 2015). Gut Inflammation and Immunity: What Is The Role Of The Human Gut Virome? Mediators of Inflammation 2015(326032):1-7.
[cited by applicant]
Galperin, M.Y. (Dec. 2013). “Genome Diversity of Spore-Forming Firmicutes,” Microbiology Spectrum 1(2):TBS-0015-2012, 27 pages.
[cited by applicant]
Garon, E.B. et al. (Oct. 2015). “Current Perspectives In Immunotherapy For Non-Small Cell Lung Cancer,” Seminars In Oncology 42(5 Supp. 2):S11-S18.
[cited by applicant]
Garrett W.S. et al. (Oct. 5, 2007). “Communicable Ulcerative Colitis Induced By T-Bet Deficiency In The Innate Immune System,” Cell 131(1):33-45, 23 pages.
[cited by applicant]
Golubovskaya, V. et al. (Mar. 15, 2016). “Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy,” Cancers 8(36), 12 pages.
[cited by applicant]
Gomaa et al. (Jan. 28, 2014). “Programmable Removal Of Bacterial Strains By Use Of Genome-Targeting CRISPR-Cas Systems,” mBio, 5(1):e000928-13, pp. 1-9.
[cited by applicant]
Gomaa, A.A. et al. (Jan./Feb. 2014). Supplemental Material to “Programmable Removal of Bacterial Strains by Use of GenomeTargeting CRISPR-Cas Systems,” American Society for Microbiology 5(1):1-9.
[cited by applicant]
Gudbergsdottir, S. et al. (2011, e-pub. Nov. 18, 2010). “Dynamic Properties of The Sulfolobus CRISPR/Cas and CRISPR/Cmr Systems When Challenged With Vector-Borne Viral and Plasmid Genes and Protospacers,” Molecular Micr…
[cited by applicant]
Guedan, S. et al. (Aug. 14, 2014). “ICOS-Based Chimeric Antigen Receptors Program Bipolar TH17/TH1 Cells,” Blood 124(7):1070-1080.
[cited by applicant]
Hargreaves, K.R. et al. (Aug. 26, 2014). “Abundant and Diverse Clustered Regularly Interspaced Short Palindromic Repeat Spacers in Clostridium difficile Strains and Prophages Target Multiple Phage Types within This Path…
[cited by applicant]
Harrington, L.E. (Nov. 2005, e-pub. Oct. 2, 2005). “Interleukin 17-producing CD4+ Effector T Cells Develop Via a Lineage Distinct From The T Helper Type 1 and 2 Lineages,” Nat. Immunol. 6(11):1123-1132.
[cited by applicant]
Hooper, L.V. et al. (Jun. 8, 2012). “Interactions Between The Microbiota and The Immune System,” Science 336 (6086):1268-1273, 16 pages.
[cited by applicant]
Horvath, P. et al. (2008, e-pub. Dec. 7, 2007). “Diversity, Activity, and Evolution Of CRISPR Loci In
[cited by applicant]
Huddleston, J.R. (Jun. 20, 2014). “Horizontal Gene Transfer In The Human Gastrointestinal Tract: Potential Spread Of Antibiotic Resistance Genes,” Infection and Drug Resistance 7:167-176.
[cited by applicant]
International Search Report and The Written Opinion of the International Searching Authority for PCT/EP2018/066954, mailed Oct. 23, 2018, filed Jun. 25, 2018, 14 pages.
[cited by applicant]
International Search Report for PCT/EP2016/059803, mailed Jun. 30, 2016, filed May 3, 2016, 6 pages.
[cited by applicant]
International Search Report for PCT/EP2018/082053, mailed Mar. 14, 2019, filed Nov. 21, 2018, 9 pages.
[cited by applicant]
International Search Report for PCT/EP2019/077760, mailed Mar. 6, 2020, filed Oct. 14, 2019, 15 pages.
[cited by applicant]
Ivanov, I.I. et al. (May 2010). “Segmented Filamentous Bacteria Take The Stage,” Muscosal Immunol. 3(3):209-212, 7 pages.
[cited by applicant]
Jiang, W. et al. (Nov. 2013). “Demonstration Of CRISPR/Cas9/sgRNA-Mediated Targeted Gene Modification In
[cited by applicant]
Jin, Y. et al. (2019, e-pub. Apr. 23, 2019). “The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC,” Journal of Thoracic Oncology…
[cited by applicant]
Jinek et al. (Aug. 17, 2012). “A Programmable Dual-RNA-Guided DNA Endonuclease In Adaptive Bacterial Immunity,” Science 337(6096):816-821.
[cited by applicant]
Kanhere, A. et al. (2005). Structural Properties of Promoters: Similarities and Differences Between Prokaryotes and Eukaryotes Nucleic Acids Research 33(10):3165-3175.
[cited by applicant]
Khoja, L. et al. (2015). “Pembrolizumab,” Journal For ImmunoTherapy Of Cancer 3(36):1-13.
[cited by applicant]
Kim, J.-S. (2016). “CRISPR/Cas9-Mediated Re-Sensitization of Antibiotic-Resistant
[cited by applicant]
Kochenderfer, J.N. et al. (Sep. 2009). “Construction and Pre-clinical Evaluation Of An Anti-CD19 Chimeric Antigen Receptor,” J. Immunother. 32(7):689-702, 26 pages.
[cited by applicant]
Kosiewicz, M.M. et al. (2014, e-pub. Mar. 26, 2014). “Relationship Between Gut Microbiota and Development of T Cell Associated Disease,” FEBS Lett. 588:4195-4206.
[cited by applicant]
Krom, R.J. et al. (Jul. 5, 2015). “Engineered Phagemids for Nonlytic, Targeted Antibacterial Therapies,” Nano Letters 15(7):4808-4813.
[cited by applicant]
Leon, L.M. et al. (Apr. 2018). “How Bacteria Control the CRISPR-Cas Arsenal,” Current Opinion in Microbiology 42:87-95, 17 pages.
[cited by applicant]
Li, Q. et al. (2016, e-pub. May 23, 2016). “CRISPR-Based Genome Editing and Expression Control Systems in Clostridium acetobutyloum and Clostridium beijerinckii,” Biotechnology Journal 11:961-972.
[cited by applicant]
Lim, H.N. et al. (Jun. 28, 2011, e-pub. Jun. 13, 2011). “Fundamental Relationship Between Operon Organization and Gene Expression,” PNAS 108(26):10626-10631.
[cited by applicant]
Lopez-Sanchez, M.-J. et al. (2012, e-pub. Jul. 27, 2012). “The Highly Dynamic CRISPR1 System Of
[cited by applicant]
Ludwig, W. et al. (1985). “The Phylogenetic Position Of
[cited by applicant]
Luo, M.L. et al. (2015, e-pub. Oct. 17, 2014). “Repurposing Endogenous Type I CRISPR-Cas Systems For Programmable Gene Repression,” Nucleic Acids Research 43(1):674-681.
[cited by applicant]
Lutz, R. et al. (1997). “Independent and Tight Regulation of Transcriptional Units in
[cited by applicant]
López, P. et al. (Apr. 5, 2016). “Th17 Responses and Natural IgM Antibodies Are Related To Gut Microbiota Composition In Systemic Lupus Erythematosus Patients,” Sci. Rep. 6:24072, 12 pages.
[cited by applicant]
Magee, M.S. et al. (Nov. 2014). “Challenges To Chimeric Antigen Receptor (CAR)-T Cell Therapy For Cancer,” Discov. Med. 18(100):265-271, 6 pages.
[cited by applicant]
Mahoney, K.M. et al. (2015). “The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade In Melanoma,” Clinical Therapeutics 37(4):764-782.
[cited by applicant]
Maikova, A. et al. (Jul. 31, 2018), “New Insights Into Functions and Possible Applications of Clostridium difficile CRISPR-Cas System,” Frontiers In Microbiology 9(1740):1-8.
[cited by applicant]
Majsec, K. et al. (2016). “Cas3 Is a Limiting Factor for CRISPR-Cas Immunity in
[cited by applicant]
Makarova, K.S. et al. (2015). “Annotation and Classification of CRISPR-Cas Systems,” Methods Mol. Biol. 1311:47-75, 27 pages.
[cited by applicant]
Makarova, K.S. et al. (Feb. 27, 2017). “SnapShot: Class 1 CRISPR-Cas Systems,” Cell 168(5):946, 2 pages.
[cited by applicant]
Makarova, K.S. et al. (Nov. 2015, e-pub.May 11, 2017). “An Updated Evolutionary Classification of CRISPR—Cas Systems,” Nature Rev. Microbiol. 13(11):722-736, 31 pages.
[cited by applicant]
Mancha-Agresti, P. et al. (Mar. 2017). “A New Broad Range Plasmid for DNA Delivery in Eukaryotic Cells Using Lactic Acid Bacteria: In Vitro and In Vivo Assays,” Molecular Therapy: Methods & Clinical Development 4:83-91.
[cited by applicant]
Manica, A. et al. (2011, e-pub. Mar. 8, 2011). “In vivo Activity Of CRISPR-Mediated Virus Defence In a Hyperthermophilic Archaeon,” Molecular Microbiology 80(2):481-491.
[cited by applicant]
Marraffini, L.A. et al. (Dec. 19, 2008, e-pub. Jun. 12, 2009) “CRISPR Interference Limits Horizontal Gene Transfer In Staphylococci By Targeting DNA,” Science 322(5909):1843-1845, 7 pages.
[cited by applicant]
Mayo Clinic (2019). “Pulmonary Embolism,” retrieved from https://www.nnayoclinic.org/diseases-conditions/pulnnonary-ennbolisnn/synnptonns-causes/syc-20354647, last visited Aug. 5, 2019, 8 pages.
[cited by applicant]
Mayo Clinic (2020). “Infectious Diseases,” retrieved from https://www.nnayoclinic.org/diseases-conditions/infectious-diseases/diagnosis-treatnnent/drc-20351179, last visited Jan. 17, 2020, 5 pages.
[cited by applicant]
Mayo Clinic (2020). “Malaria,” retrieved from https://www.nnayoclinic.org/diseases-conditions/nnalaria/diagnosis-treatnnent/drc-20351190, last visited Jan. 17, 2020, 3 pages.
[cited by applicant]
Mayo Clinic (2020). “Sexually Transmitted Diseases (STDs),” retrieved from https://www.nnayoclinic.org/diseases-conditions/sexually-transnnitted-diseases-stds/diagnosis-treatnnent/drc-20351246, last visited Jan. 17, 202…
[cited by applicant]
Medina-Aparicio, L. et al. (May 2011, e-pub. Mar. 11, 2011). “The CRI SPR/Cas Immune System Is an Operon Regulated by LeuO, H-NS, and Leucine-Responsive Regulatory Protein in
[cited by applicant]
Mercenier, A. (1990). “Molecular Genetics Of
[cited by applicant]
Mick, E. et al. (May 2013). “Holding a Grudge: Persisting Anti-Phage CRISPR Immunity In Multiple Human Gut Microbiomes,” RNA Biology 10(5).900-906.
[cited by applicant]
Mills, S. et al. (Jan./Feb. 2013). “Movers and Shakers: Influence Of Bacteriophages In Shaping The Mammalian Gut Microbiota,” Gut Microbes 4(1):4-16.
[cited by applicant]
Moon, B.Y. et al. (Mar. 8, 2016). “Mobilization of Genomic Islands of
[cited by applicant]
Mutalik, V.K. et al. (Apr. 2013, e-pub. Mar. 10, 2013) “Precise and Reliable Gene Expression Via Standard Transcription and Translation Initiation Elements,” Nat. Methods 10(4):354-360.
[cited by applicant]
Nakade, S. et al. (2017, e-pub. Jan. 31, 2017). “Cas9, Cpf1 and C2c1/2/3—What's Next?” Bioengineered 8(3):265-273.
[cited by applicant]
Nakamura, S. et al. (Nov. 2008). “Metagenomic Diagnosis Of Bacterial Infections,” Emerging Infectious Diseases 14(11):1784-1786.
[cited by applicant]
Nale, J.Y. et al. (2012). “Diverse Temperate Bacteriophage Carriage In Clostridium Difficile 027 Strains,” PloS One 7(5):e37263, 9 pages.
[cited by applicant]
Navarre, W.W. et al. (2007). “Silencing of Xenogeneic DNA by H-NS—Facilitation Of Lateral Gene Transfer In Bacteria By A Defense System That Recognizes Foreign DNA,” Genes & Development 21:1456-1471.
[cited by applicant]
Nelson, M.H. et al. (2015). “Harnessing The Microbiome To Enhance Cancer Immunotherapy,” Journal of Immunology Research 2015: Article 368736, 12 pages.
[cited by applicant]
Non-Final Office Action, mailed Aug. 20, 2021, for U.S. Appl. No. 17/195,157, filed Mar. 8, 2021, 17 pages.
[cited by applicant]
Non-Final Office Action, mailed Jan. 20, 2022, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 91 pages.
[cited by applicant]
Non-Final Office Action, mailed Jun. 7, 2023, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 11 pages.
[cited by applicant]
Non-Final Office Action, mailed May 25, 2021, for U.S. Appl. No. 17/166,941, filed Feb. 3, 2021, 17 pages.
[cited by applicant]
Non-Final Office Action, mailed Nov. 25, 2019, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 8 pages.
[cited by applicant]
Non-Final Office Action, mailed Nov. 30, 2020, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 35 pages.
[cited by applicant]
Norris, J.S. et al. (2000). “Prokaryotic Gene Therapy To Combat Multidrug Resistant Bacterial Infection,” Gene Therapy 7:723-725.
[cited by applicant]
Novick, R. (May 18, 2018). “Reincarnation Of A Staphylococcal Pathogenicity Island As An antibacterial Drone,” 5th World Congress On Targeting Infectious Diseases: Targeting Phage & Antibiotic Resistance: Phage Therapy …
[cited by applicant]
Nowak, P. et al. (Nov. 28, 2015). “Gut Microbiota Diversity Predicts Immune Status In HIV-1 Infection,” AIDS 29(18):2409-2418.
[cited by applicant]
O'Hara, B.J. et al. (Jun. 8, 2017). “A Highly Specific Phage Defense System Is A Conserved Feature Of The Vibrio cholera Mobilome,” PLOS Genetics 13(6):e1006838, 17 pages.
[cited by applicant]
Park, A. (Oct. 18, 2011). “A Surprising Link Between Bacteria and Colon Cancer,” Cancer retrieved from http://healthlande.time.com/2011/10/18/a-surprising-link-between-bacteria-and-colon-cancer/, last visited Aug. 27, 2…
[cited by applicant]
Park, H. et al. (2005). “A Distinct Lineage Of CD4 T Cells Regulates Tissue Inflammation By Producing Interleukin 17,” Nat. Immunol. 6(11):1133-1141, 24 pages.
[cited by applicant]
Patterson, A.G. et al. (2017, e-pub. Mar. 27, 2017). “Regulation of CRISPR-Cas Adaptive Immune Systems,” Current Opinion in Microbiology 37:1-7.
[cited by applicant]
Pawluk, A. et al. (Apr. 15, 2014). “A New Group Of Phage Anti-CRISPR Genes Inhibits The Type I-E CRISPR-Cas System Of Pseudomonas aeruginosa,” mBio. 5(2):e00896.
[cited by applicant]
PCT Application No. PCT/EP2018/0071454.(Copy not submitted herewith pursuant to the waiver of 37 C.F.R. 1.98(a) (2)(iii) issued by the Office on Sep. 21, 2004).
[cited by applicant]
Penades, J.R. et al. (Nov. 2015). “The Phage-Inducible Chromosomal Islands: A Family of Highly Evolved Molecular Parasites,” Annual Review of Virology 2:181-201.
[cited by applicant]
Petris, G. et al. (May 22, 2017). “Hit and Go CAS9 Delivered Through a Lentiviral Based Self-Limiting Circuit,” Nature Communications 8:15334, 9 pages.
[cited by applicant]
Pires, D.P. et al. (Sep. 2016, e-pub. Jun. 1, 2016), “Genetically Engineered Phages: A Review of Advances Over the Last Decade,” Microbiology and Molecular Biology Reviews 80(3):523-543.
[cited by applicant]
Pul, Ü. et al. (2010, e-pub. Feb. 17, 2010). “Identification and Characterization of
[cited by applicant]